

May 2025 Medical Drug Recommendations to EBD Commission

| Drug | Treating Diagnosis | EBD Recommendation (based on input from EBRx and HA) | Comment | Cost (AWP unless otherwise mentioned) | Commission Recommendation | Board of Finance Recommendation |
|--|---|--|--|--|------------------------------|------------------------------------|
| Cortrophin (corticotropin SC) | Psoriasis, infantile spasms, numerous other diagnoses that have limited data | Exclude | Line extension of Acthar gel (excluded product). Alternative is IV prednisolone. | \$8,905 per 80units/mL syringe | <i>Approved 5/6/25</i> | <i>Approved 5/12/25</i> |
| Encelto (revakinagene taroretccl-LWEY opthal implant) | Idiopathic macular telangiectasia type 2 (MacTel) | Exclude | Unknown MCID (did it reduce blindness?), durability unknown | \$300,000 per intravitreal implant | <i>Approved 5/6/25</i> | <i>Approved 5/12/25</i> |
| Eylea (aflibercept) | Macular degeneration, diabetic macular edema, diabetic retinopathy | No EBRx Restrictions | Adding Eylea back to formulary alongside biosimilar Pavblu. Will reevaluate for cost and availability in 1 year. | \$2,275.50 per 2mg/0.05mL syringe | <i>Approved 5/6/25</i> | <i>Approved 5/12/25</i> |
| Grafapex (treosulfan) | In combination with fludarabine to prep for allogeneic hematopoietic stem cell transplant (to treat AML or MDS) | Exclude | Trial only compared to reduced intensity busulfan (not the standard dosing). Generic busulfan is cheaper. | \$39,528 per course for 1.8m ² and 75kg patient | <i>Approved 5/6/25</i> | <i>Approved 5/12/25</i> |
| Niktimvo (axatilimab-csfr) | Chronic graft-versus-host disease | Cover with EBRx PA | Considered last line for graft rejection, Phase 2 trail, reduces symptom burden | \$27,720 per 28 days | <i>Approved 5/6/25</i> | <i>Approved 5/12/25</i> |
| Otufli (Ustekinumab- AAUZ) | Plaque psoriasis, psoriatic arthritis, Chron's disease and ulcerative colitis | Exclude | Preferred alternatives are Selarsdi, Yesintek or Steqeyma (matches pharmacy benefit) | \$4,343.48 per 90mg SC syringe | <i>Approved 5/6/25</i> | <i>Approved 5/12/25</i> |
| Rapiblyk (landiolol) | For short term reduction of Ventricular rate in adults with SVT | Exclude | Excluded in infusion center, when given in ER or ICU then it rolls into the DRG charge. Esmolol is cheaper. | \$1,020 per 280mg vial | <i>Approved 5/6/25</i> | <i>Approved 5/12/25</i> |
| Tecartus (brexucabtagene) | Relapsed or refractory mantle cell lymphoma | Cover with EBRx PA | CAR-T has better OS but higher rate of temporary SE compared to Obe- cel, durable results. Will notify HA with each new approval. | \$447,600 each | <i>Approved 5/6/25</i> | <i>Approved 5/12/25</i> |

NTM = new to market, No EBRx Restrictions means that policy defers to Health Advantage